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Sirtuins have emerged in recent years as critical regulators of metabolism, influencing numerous facets of
energy and nutrient homeostasis. Here, we review recent advances on the role of this fascinating family of
mammalian proteins and their well-orchestrated function in modulating mitochondrial activity.The discovery of the Sir2 protein as a central regulator of life
span in yeast more than a decade ago catalyzed an explosion
in longevity research and in particularly in studies of the relation-
ship between metabolic control and aging (Kaeberlein et al.,
1999; Imai and Guarente, 2010). The subsequent identification
of a family of Sir2-related proteins, collectively known as sirtuins,
across many species has identified conserved mechanisms of
organismal aging that continue to capture the attention of both
the academic community and the general public. It is now
apparent that sirtuins mediate wide-ranging biological functions,
spanning from DNA repair to energy metabolism and oxidative
stress responses. Moreover, in addition to aging, alterations in
sirtuin function have central roles in neurodegenerative
diseases, cancer, circadian rhythms, and much more. Although
the closest mammalian homolog of Sir2, SIRT1, has been at
center stage for many years, recent work has described distinct
and fascinating roles for the other sirtuin family proteins. These
studies do not upstage SIRT1, but rather demonstrate that the
various members of this protein family act in a carefully orches-
trated manner to coordinate metabolic homeostasis. In this
Minireview, we will discuss recent discoveries in the biology of
sirtuins with a particular focus on functions in mitochondrial
physiology. Our discussion will include both sirtuin family
members that directly localize to the mitochondria and those
that localize elsewhere in the cell yet directly impacting mito-
chondrial activity by means of influencing the production of
metabolic intermediates. Mammalian sirtuins represent essen-
tial players in bridging this organelle with the rest of the cell—
revealing that indeed, ‘‘no mitochondrion is an island, entire of
itself.’’Sirtuins and Mitochondria Function
There are seven sirtuins in mammals (SIRT1-7). These proteins
share an evolutionarily conserved catalytic core domain but
show little similarity in other regions. Sirtuins exhibit distinct
subcellular localizations: SIRT1, SIRT6, and SIRT7 are mainly
nuclear, SIRT2 is primarily found in the cytosol, and SIRT3,
SIRT4, and SIRT5 are mitochondrial proteins. There is some
evidence that the mitochondrial targeting of some family
members may be dynamic as SIRT1 has been reported to be
present in the mitochondria (Aquilano et al., 2010) and SIRT3
can be found in other cellular compartments (Verdin et al.,
2010). However, the physiological relevance of this ‘‘ectopic’’
localization remains to be determined.Sirtuins exert their biological functions primarily through their
capacity to modify proteins via catalyzing either deacetylation
or ADP ribosylation. NAD+ is required as a cofactor for this cata-
lytic activity. As NAD+—and its reduced form NADH—serves as
an essential electron carrier in a wide range of metabolic pro-
cesses, sirtuin activity is directly linked to cellular metabolic
status and nutrient availability. In turn, sirtuins themselves are
important modulators of multiple metabolic processes, including
energy production, the urea cycle, fatty acid metabolism, and
acetate metabolism.
The metabolism of glucose, fatty acid, and amino acids is
linked since key metabolic intermediates are shared between
the individual pathways. The mitochondria provide the hub that
integrates these pathways, serving as a critical site for the
production and exchange of metabolic intermediates (Figure 1).
Hence, the mitochondria play a critical role in orchestrating
complex metabolic networks in order to maintain proper homeo-
stasis. Notably, mitochondrial proteins are subject to posttrans-
lational modifications in response to changes in physiological
conditions. For instance, proteomic studies have shown that a
large fraction of mitochondrial proteins are acetylated (reviewed
in Verdin et al., 2010). Strikingly, acetyl-lysines are found in
almost all the enzymes involved in the TCA cycle, the urea cycle
and fatty acid metabolism—key mitochondrial processes—
underscoring the significance of this modification in mitochon-
drial function (reviewed in Verdin et al., 2010). As NAD+-depen-
dent deacetylases, sirtuins are well positioned to control the
dynamics of mitochondrial protein acetylation, thus potentially
influencing every aspect of mitochondrial function. Indeed, it
has been shown that mitochondrial biogenesis itself is regulated
by both SIRT1 and SIRT3, through a process involving the tran-
scriptional coactivator PGC1a (Lomb et al., 2010), as it will be
discussedbelow. Furthermore, not onlybiogenesisbut alsomito-
chondrial degradation seems to be regulated by sirtuins, since
autophagy of damaged mitochondria in aged kidney is also
SIRT1 dependent (Kume et al., 2010; reviewed in Finkel et al.,
2009). Below, we discuss the complex multileveled contribution
of eachmember of the sirtuin family to mitochondrial physiology.Energy Production Pathways
The Insulin Signaling Pathway and Mitochondrial
Activity
Insulin—secreted by pancreatic b cells upon nutrient stimula-
tion—is one of the most important regulators of nutrientCell Metabolism 13, June 8, 2011 ª2011 Elsevier Inc. 621
Figure 1. Sirtuins’ Regulation of Mitochondrial Biology
Overview diagram indicating the main metabolic pathways in the mitochondria and the different roles sirtuins play in those pathways. Green arrows indicate
activating effects; red bars denote inhibiting functions.
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the IRS-PI3K-AKT-mTOR/FOXO1 signaling pathway, promoting
protein synthesis, glycolysis, glucose storage, and lipid syn-
thesis and storage, while inhibiting gluconeogenesis and
ketogenesis (Cheng et al., 2010). Insulin signaling modulates
mitochondrial function by altering these pathways, and is in
turn regulated by the activity of this organelle (Figure 1). Notably,
insulin resistance—a hallmark of metabolic syndrome and type II
diabetes—is accompanied by reduction of mitochondrial
OXPHOS activity (Cheng et al., 2010). On the other hand, reac-
tive oxygen species (ROS) produced during mitochondrial
OXPHOS promote insulin signaling through oxidation of insulin
receptor and inhibition of phosphatases, such as PTP1B and
PTEN (Cheng et al., 2010).
Several sirtuins exert their control over metabolic homeostasis
by tightly linking insulin secretion to mitochondria activity. In the
pancreas, SIRT1 acts as a positive regulator of insulin secretion,
through directly binding to and repressing the uncoupling protein
2 (UCP2) gene, which encodes a mitochondrial proton trans-
porter (reviewed in Finkel et al., 2009). UCP2 resides on the inner
membrane of mitochondria and promotes proton leakage across
the mitochondria membrane, thus uncoupling oxidative respira-622 Cell Metabolism 13, June 8, 2011 ª2011 Elsevier Inc.tion from ATP generation. The reduced ATP/ADP ratio in turn
blunts insulin secretion. Notably, conditions of short-term fasting
reduced the levels of NAD+ in the pancreas, in turn decreasing
SIRT1 activity and leading to upregulation of UCP2 with a
concomitant dampening in insulin secretion (Imai and Guarente,
2010). UCP2 plays a critical role in favoring fatty acidmetabolism
over glucose metabolism, and therefore it will be interesting to
determine whether SIRT1, through its role in controlling UCP2,
also modulate lipid metabolism beyond its role in insulin secre-
tion. Notably, a recent study reported that SIRT1 mediates
resveratrol-induced increase of insulin secretion through a
mechanism independent of UCP2 transcriptional repression
(Vetterli et al., 2011). In this context, future studies will be
required to determine the relevance of the UCP2 pathway in
SIRT1-regulated insulin secretion.
In contrast to SIRT1, SIRT4 appears to repress insulin secre-
tion, by modulating the activity of glutamate dehydrogenase
(GDH), a mitochondrial enzyme that converts glutamate into
the TCA-cycle intermediate a-ketoglutarate (Verdin et al.,
2010). GDH is known to promote amino acid-stimulated insulin
secretion. Under normal diet conditions, GDH is ADP-ribosy-
lated and repressed by SIRT4, allowing cells to use glucose as
Figure 2. Differential Effect for Sirtuins in Liver and Muscle
Metabolism
Under nutrient stress, SIRT1 is activated in liver, in turn modulating the activity
of multiple downstream pathways to promote gluconeogenesis, mitochondrial
biogenesis, and fatty acid oxidation, while inhibiting lipogenesis and glycolysis
(A). In contrast, nutrient stress in muscle appears to enhance glycolysis,
possibly through SIRT1-mediated downregulation of SIRT6 (B).
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low-glucose conditions, however, the repressive control on
GDH is relaxed in order to increase the amount of a-ketogluta-
rate, which fuels the TCA cycle for ATP production to meet the
energy demands of cells (Verdin et al., 2010). Since SIRT4
protein levels do not seem to change during CR, it will be inter-
esting to investigate how SIRT4 activity is regulated under
different nutrient conditions. Interestingly, GDH can be deacety-
lated by another mitochondrial sirtuin, SIRT3 (Verdin et al., 2010).
At least in vitro, acetylation of GDH reduces its activity while
SIRT3 mediated deacetylation of GDH activates it (Verdin
et al., 2010). Since no significant changes of GDH activity can
be detected in SIRT3-deficient animals, the physiological signif-
icance of the SIRT3-GDH regulatory pathway remains to be
determined (Nakagawa et al., 2009).
It is striking to note that SIRT1, SIRT4, and possibly SIRT3 act
in an opposite albeit coordinated manner to regulate insulin
secretion in response to a range of dietary conditions, including
ad libitum feeding, short-term fasting, and chronic calorie
restriction. Although our mechanistic understanding of this
coordination is incomplete, it is clear that the crosstalk between
sirtuins relates to distinct and critical functions in maintaining
metabolic homeostasis, a reoccurring theme that will be
mentioned throughout this Minireview.
Glycolysis
Glycolysis is the first step in a metabolic pathway to obtain
high-energy compounds (e.g., ATP) from glucose. Glucose, the
primary carbon source of energy in most cells, is imported by
glucose transporters (GLUTs) and metabolized through a series
of steps to generate pyruvate (Figure 1). Pyruvate can be further
oxidized into Acetyl-CoA, to enter the tricarboxylic acid (TCA)
cycle in the mitochondria. Under conditions of nutrient excess,
most of the glucose is converted into pyruvate to enter mito-
chondrial respiration, whereas, under low glucose or low oxygen
conditions, pyruvate is diverted to produce lactate through
anaerobic glycolysis. A key regulator of this glycolytic switch is
hypoxia-induced factor 1a (Hif1a), a transcription factor that is
activated during hypoglycemia or hypoxia, in turn inducing
expression of multiple genes that promote anaerobic glycolysis
while inhibiting the TCA cycle (Figure 1). Although anaerobic
glycolysis is far less energy-efficient (2 mol ATP/mol of glucose,
against 36 mol ATP/mol glucose in the TCA cycle), it provides
critical intermediate metabolites necessary to maintain macro-
molecular biosynthesis. Such a switch provides an important
advantage to rapidly dividing cells, as is the case in tumor cells
(i.e., the well recognized ‘‘Warburg effect’’) (Warburg, 1956).
SIRT3 has recently been found to indirectly inhibit Hif1a
activity through ROS reduction, thereby repressing glycolysis
(Finley et al., 2011). A more direct connection between sirtuins
and Hif1a comes from SIRT1 and SIRT6: SIRT1 represses
glycolysis by inhibiting Hif1a activity through direct interaction
and deacetylation (Lim et al., 2010). Interestingly, SIRT6 also
suppresses glycolysis under normal conditions through core-
pressing Hif1a target genes, via functioning as a histone H3K9
deacetylase at the promoters of these glycolytic genes (Zhong
et al., 2010) (Figure 1). As Hif1a is largely, although not com-
pletely inactivated by proteasomal degradation under high
glucose or high oxygen conditions, this extra layer of regulation
imposed by SIRT1 and SIRT6 may maximize ATP production,inhibiting unnecessary lactate production, while at the same
time allowing rapid activation of this glycolytic switch under
conditions of nutrient stress.
Recent studies further illustrate the potential crosstalk
between SIRT1 and SIRT6. Kim and colleagues found that
SIRT1 enhances SIRT6 expression by interacting with FOXO3a
and NRF1 at the SIRT6 promoter (Kim et al., 2010) (Figure 1).
SIRT1 has previously been shown to increase under conditions
of nutrient scarcity, causing in liver increased mitochondrial bio-
genesis, increased gluconeogenesis and reduced glycolysis; in
muscle, SIRT1 activation also leads to increased mitochondrial
biogenesis, in turn inducing in this tissue fatty acid oxidation.
These effects have been attributed to increased SIRT1 activity
following AMP-activated protein kinase (AMPK)-mediated
increase in cellular NAD+ levels. In turn, SIRT1 mediates the
activation of the PGC1-a transcriptional coactivator, a known
modulator of this metabolic adaptation to nutrient stress (re-
viewed in Verdin et al., 2010) (Figure 2). Kim et al. propose
another layer of regulation in studies that employed liver-specific
SIRT6 deficient mice. They show that SIRT1 also activates SIRT6
in the liver, which further supports the switch from glycolysis
toward fatty acid oxidation. Of note, initial studies found that
germline SIRT6 KO mice die from a lethal hypoglycemia due to
increased glycolysis and concomitant uncontrolled glucose
uptake in skeletal muscle and fat (Figure 2) (Zhong et al., 2010).
As opposed to liver, activation of SIRT1 in muscle during nutrient
stress is expected to decrease SIRT6 activity, favoring a switch
toward glycolysis, an hypothesis that remain to be tested.Cell Metabolism 13, June 8, 2011 ª2011 Elsevier Inc. 623
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The TCA cycle is at the core of a network of cellular metabolic
processes. It links glycolysis and pyruvate oxidation with oxida-
tive phosphorylation (Figure 1). In addition, amino acids and fatty
acids can be converted to acetyl-CoA and enter the TCA cycle.
The TCA cycle itself also provides various metabolic intermedi-
ates for amino acid synthesis. SIRT3 may potentially affect the
TCA cycle by deacetylating isocitrate dehydrogenase 2 (Idh2)
(Someya et al., 2010) and succinate dehydrogenase complex
subunit A (SdhA) (Cimen et al., 2010), thereby increasing their
enzymatic activity. Idh2 is responsible for catalyzing the conver-
sion of isocitrate to a-ketoglutarate and CO2, in this way
reducing NAD+ to NADH, while SdhA converts succinate to
fumarate. Whereas SIRT3-mediated deacetylation of Idh2 has
been linked to protection against age-associated hearing loss
(see below), it remains as yet unclear whether SIRT3 deacetyla-
tion of these TCA components affects the TCA cycle per se. In
this context, it will be interesting to determine whether point
mutants mimicking constitutively acetylated proteins exhibit
TCA cycle defects, an experiment that will validate the role of
SIRT3 in modulating the Krebs cycle.
Electron Transport Chain, Oxidative Stress,
and Mitochondrial Dependent Apoptosis
Sirtuins play important roles in regulating the electron transport
chain (ETC). First, SIRT3 augments the activity of complex I
through direct interaction and deacetylation of several of its
subunits. In line with this observation, ATP levels are reduced
over 50% in the heart, liver and kidney in SIRT3-deficient mice
(Finkel et al., 2009), highlighting the importance of SIRT3 in
maintaining basal levels of ATP. Second, the above-mentioned
SIRT3 substrate and TCA cycle enzyme, SdhA, is also a compo-
nent of complex II. The activation of SdhA caused by SIRT3
deacetylation stimulates complex II and help cells cope with
the increased levels of NAD+ that follows nutrient deprivation
(Cimen et al., 2010). Third, ATP synthase a and cytochrome C
are deacetylated by SIRT3 and SIRT5, respectively, although
the physiological significance of these interactions remains to
be explored (reviewed in Verdin et al., 2010).
A common theme emerges from these studies: lack of nutri-
ents increases the levels of NAD+, activating sirtuins (mainly
SIRT1 and SIRT3 at present), which in turn enhance ATP produc-
tion in order to meet energy demands. At the same time, sirtuins
keep this machinery from overdrive, protecting cells from stress-
induced apoptosis, as discussed below.
ETC is a major site for the production of ROS, which can serve
as signaling molecules vital for normal cellular functions. How-
ever, abnormal ROS production can lead to serious conse-
quences, such as oxidation of protein, fatty acids, and lipids,
as well as severe DNA damage, which can impair cell viability.
Cells protect themselves against ROS by expressing a group
of antioxidant enzymes, such as SOD2/MnSOD, which convert
superoxide to hydrogen peroxide.
Sirtuins appear to be at the center of ROS metabolic conver-
sion, as well as influencing the direct apoptotic response to
ROS. Notably, SIRT3-deficient cells experience increased ROS
levels and genomic instability when exposed to stress, and these
factors lead to tumorigenesis in vivo (Verdin et al., 2010). As
mentioned above, Finley et al. extended this notion one step
further by demonstrating that increased ROS level stabilizes624 Cell Metabolism 13, June 8, 2011 ª2011 Elsevier Inc.Hif1a, contributing to a metabolic reprogramming in cancer cells
(Finley et al., 2011). How does SIRT3 reduce ROS? Two studies
have independently demonstrated that SIRT3 directly deacety-
lates and activates SOD2/MnSOD in response to stress (Tao
et al., 2010; Qiu et al., 2010). Intriguingly, the lysine residues
deacetylated by SIRT3 identified by the two groups are different
(K122 in one and K53/K89 in the other), raising the question of
how and whether these two events are coordinated. In addition
to direct deacetylation of SOD2/MnSOD, SIRT3 also interacts
with the FOXO3a transcription factor in the mitochondria and
increases its binding to the promoters of mitochondrial genes.
FOXO3a in turn increases expression of a cohort of genes that
encode superoxide scavengers, such as SOD2/MnSOD,
SCO2, and Catalase (Verdin et al., 2010). Interestingly, nuclear
localization of SIRT1 in failing hearts has been shown to induce
MnSOD expression as a protective measure to promote cardio-
myocyte survival (Tanno et al., 2010), although the molecular
mechanism behind this induction has not been fully explored.
In addition to their roles in ROSmetabolism, sirtuins appear to
exert a protective function against mitochondria-dependent
apoptosis. SIRT3 and SIRT4 are required for maintaining
mitochondrial NAD+ pool mediated by NAD+ biosynthesis
enzyme NAMPT to protect cells from apoptosis induced by
genotoxic reagents (reviewed in Finkel et al., 2009), although
the mechanisms underline this protective role is unclear. The
authors proposed that mitochondrial permeabilitytransition
pore (mPTP) might be involved, which indeed turned out to be
the case. Cyclophilin-D, a component of mPTP, is found to be
deactylated by SIRT3. Consequently, mPTP opening is inhibited,
and apoptosis prevented (Shulga and Pastorino, 2010; Hafner
et al., 2010). Several other targets of SIRT3 have been identified
to promote SIRT3-dependent protection under stress: genotoxic
and oxidative stress upregulates SIRT3 protein levels, protecting
mouse cardiomyocytes from stress-induced apoptosis through
deacetylation of Ku70 (Sundaresan et al., 2008). As mentioned
above, SIRT3 mediated the protective effects of calorie restric-
tion on age-associated hearing loss by deacetylating and
activating Idh2, in turn reducing ROS and protecting against
apoptosis of spiral ganglion neurons and sensory hair cells
(Someya et al., 2010). Overall, SIRT3 seems to work asmultilayer
coordinators to ensure that cells are properly protected against
oxidative damage, whereas the function of SIRT4 in this process,
although essential, remains to be explored.
In this context, SIRT5 can deacetylate cytochromeC, a protein
essential for apoptosis, suggesting a role for this sirtuin in
stress-induced, mitochondrial-dependent apoptosis (Verdin
et al., 2010). Despite this biochemical observation, it remains
unclear whether SIRT5-dependent deacetylation of cytochrome
c inhibits or induces apoptosis, and therefore it physiological
relevance remains unknown.
Urea Cycle
During periods of fasting, amino acids in muscle are catabolized
as a carbon source for gluconeogenesis, and the newly formed
glucose is metabolized for energy. However, ammonia gener-
ated in this process is highly toxic and must be converted to
urea for proper excretion, a process that occurs through the
urea cycle. The rate limiting first step of the urea cycle converts
ammonia to carbamoyl phosphate and is catalyzed by
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found to interact with and deacetylate CPS1, thus enhancing its
enzymatic activity (Nakagawa et al., 2009) (Figure 1). SIRT5-defi-
cient mice exhibited increased CPS1 acetylation and decreased
CPS1 activity. Concomitantly, these animals suffer from hyper-
ammonia during starvation. In addition, starvation activates
SIRT5, suggesting that SIRT5 positively regulates the urea cycle
through CPS1 deacetylation during fasting. Notably, an earlier
report showed increased CPS1 acetylation levels during CR
(Schwer et al., 2009). These seemingly contradictory results
suggest that different levels of nutrient limitation might affect
the requirement for amino acid catabolism and the urea cycle.
The second step in the urea cycle, where carbamoyl phosphate
is converted to citrulline by ornithine transcarbamoylase (OTC),
is regulated by another mitochondrial sirtuin, SIRT3. SIRT3
directly deacetylates OTC and stimulates its enzymatic activity
during CR (Hallows et al., 2011) (Figure 1). Although unexplored,
it is tempting to speculate that increased ammonia levels might
coordinately stimulate activity of both SIRT3 and SIRT5, which
in turn will act upon CPS1 and OTC, respectively, to robustly
activate the urea cycle. Future studies would be required to
test this possibility.
Lipid and Acetate Metabolism
Lipid homeostasis depends on a well-orchestrated balance
between fatty acid synthesis, lipid oxidation, and lipid storage.
This important metabolic pathway is also tightly intertwined
with carbohydrate and protein metabolism. Therefore, control
of the latter two pathways by sirtuins discussed above also likely
causes indirect effects on lipid metabolism. In addition, several
studies have defined direct roles for sirtuins in lipid regulation
as well (Lomb et al., 2010). For example, SIRT1 and SIRT2 nega-
tively regulate adipocyte differentiation and triglyceride storage
through PPARg repression and FOXO1 deacetylation, respec-
tively (Lomb et al., 2010). Liver-specific deletion of SIRT1 in
mice impairs the fatty acid b oxidation and leads to hepatic stea-
tosis and inflammation under high fat diet, possibly through
direct interaction between SIRT1, PPARa and PGC-1a (reviewed
in Lomb et al., 2010). Interestingly, another study using the same
animals, when challenged with western style diet at an older age,
produced contradictory results (reviewed in Lomb et al., 2010).
These results suggest that there might be different regulatory
mechanisms for SIRT1 on liver physiology at different stages in
life. Recently, the significance of mitochondrial sirtuins on lipid
metabolism has been put forward by several reports. SIRT3
deacetylates long-chain acyl co-A dehydrogenase (LCAD) and
promotes mitochondrial fatty acid b-oxidation (FAO) upon fast-
ing (reviewed in Verdin et al., 2010). Mitochondrial 3-hydroxy-
3-methylglutaryl CoA synthase 2 (HMGCS2) is an additional
novel substrate of SIRT3 that contributes to lipid utilization (Shi-
mazu et al., 2010). Upon fasting, HMGCS2 is deacetylated and
activated by SIRT3 in order to generate ketone bodies from
acetyl-CoA, which is produced by FAO in the liver. Ketone
bodies can then be used by extrahepatic tissues—such as
brain—as an alternative energy source. In addition, a recent pro-
teomics study revealed several other potential SIRT3 substrates
in FAO (Smith et al., 2011). On the other hand, SIRT4 seems to
have a negative role on FAO, since knocking down SIRT4 results
in increased FAO gene expression. Curiously, this effect is SIRT1dependent, and SIRT4 knockdown is accompanied by increased
expression of SIRT1 and SIRT3 (Nasrin et al., 2010), revealing
another intriguing example of crosstalk among sirtuins (Figure 1).
Acetate, through its reversible conversion to Acetyl-CoA,
provides an alternative carbon source for various metabolic
pathways, such as amino acid synthesis, fatty acid metabolism,
and the TCA cycle (Figure 1). AceCS2 catalyzes this reaction and
plays important roles in thermogenesis during fasting conditions.
Notably, SIRT3 can deacetylate AceCS2 and promote its activity
(reviewed in Finkel et al., 2009). Acetyl-CoA generated in this
process can be used in the TCA cycle to promote aerobic respi-
ration and subsequent oxidative phosphorylation, or diverted for
fatty acid synthesis (FAS). Therefore, through activation of
AceCS2, SIRT3 also indirectly modulates both the TCA cycle
and FAS.
Closing Remarks and Perspective
Over the last decade, studies on the biology of sirtuins have led
to a remarkable growth in our knowledge ofmetabolic processes
involving mitochondrial function. A number of sirtuins have
emerged as ‘‘master regulators’’ of mitochondrial metabolism,
acting as sensors of NAD/NADH levels, in turn to convert
information about nutrient status into changes in cell physiology,
by way of deacetylating or ADP-ribosylating key enzymes in
multiple pathways (Figure 1). In the next few years we will
certainly witness the expansion of this list of sirtuin substrates
and the deciphering of the crosstalk among the different sirtuins.
In addition to providing detailed understanding of mitochondrial
function, this work is likely to open up new opportunities for
therapeutic intervention in a broad range of metabolic and
degenerative diseases.
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